Johnson & Johnson buy The Goldman Sachs Group, Inc.
Start price
22.09.25
/
50%
€149.14
Target price
22.09.26
€158.53
Performance (%)
2.95%
Price
21:54
€153.54
Summary
This prediction is currently active. With a performance of 2.95%, the BUY prediction by The_Goldman_Sachs_Gr for Johnson & Johnson is trending in the right direction. This prediction currently runs until 22.09.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionJohnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Johnson & Johnson | 2.95% |
| iShares Core DAX® | -0.581% |
| iShares Nasdaq 100 | 0.824% |
| iShares Nikkei 225® | -0.630% |
| iShares S&P 500 | 0.643% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Johnson & Johnson diskutieren
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $185.00 to $186.00. They now have a "buy" rating on the stock.
Ratings data for JNJ provided by MarketBeat